Back to Search
Start Over
Supplemental Table 2 from Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Bortezomib pharmacokinetic parameters following a single intravenous 1.3 mg/m2 bolus dose and varying single intravenous doses of tabalumab
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....12a1e1c21106b1ee60f5e5bb6bc77611
- Full Text :
- https://doi.org/10.1158/1078-0432.22467209.v1